Nektar Therapeutics (NASDAQ: NKTR) stock is trading lower Monday afternoon as the market continues to assess mixed topline results from the Phase 2b REZOLVE-AA trial of rezpegaldesleukin. Here’s what ...

Nektar Therapeutics is planning to bring its interleukin-2-targeting drug candidate into a phase 3 trial for severe alopecia areata, even after the asset narrowly missed the main goal of a midstage ...

Investing.com -- Nektar Therapeutics (NASDAQ:NKTR) stock fell 5% Tuesday after the company’s Phase 2b trial of rezpegaldesleukin for alopecia areata narrowly missed its primary endpoint, despite ...

SAN FRANCISCO - Nektar Therapeutics (NASDAQ:NKTR) announced Tuesday that its investigational drug rezpegaldesleukin showed promising results in treating severe-to-very-severe alopecia areata in a ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A treatment for alopecia areata ...

Nektar Therapeutics (NKTR) has quietly transformed its performance over the past year, with the stock rising significantly from its multi year slump as investors revisit the company’s immunology ...

Additionally, on November 21, 2025, Zalevsky acquired 4,766 shares of stock options with an exercise price of $281.25, set to expire on December 17, 2028. Following these transactions, Zalevsky ...

Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

A week ago, Nektar Therapeutics (NASDAQ:NKTR) came out with a strong set of third-quarter numbers that could potentially lead to a re-rate of the stock. Nektar Therapeutics outperformed estimates, ...

SAN FRANCISCO, Nov. 6, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2025. "We have made tremendous progress ...

Results of the Resolve-AD trial with rezpegaldesleukin were better than expected. In a nutshell, it looks like it could become a top-selling treatment for eczema, an itchy autoimmune disorder that ...